Edward H. Myles Sells 7,809 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK) Stock

Scholar Rock Holding Co. (NASDAQ:SRRK - Get Free Report) CFO Edward H. Myles sold 7,809 shares of Scholar Rock stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $36.83, for a total value of $287,605.47. Following the transaction, the chief financial officer now directly owns 140,740 shares of the company's stock, valued at approximately $5,183,454.20. The trade was a 5.26 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Scholar Rock Price Performance

Shares of SRRK traded down $1.45 during mid-day trading on Friday, hitting $37.70. 717,240 shares of the company traded hands, compared to its average volume of 757,555. The company has a current ratio of 3.88, a quick ratio of 3.88 and a debt-to-equity ratio of 0.63. The business has a 50-day moving average of $41.81 and a 200 day moving average of $28.37. Scholar Rock Holding Co. has a one year low of $6.76 and a one year high of $46.98. The stock has a market capitalization of $3.53 billion, a price-to-earnings ratio of -16.04 and a beta of 0.50.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Wellington Management Group LLP lifted its stake in shares of Scholar Rock by 16.2% during the third quarter. Wellington Management Group LLP now owns 199,777 shares of the company's stock valued at $1,600,000 after acquiring an additional 27,801 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in Scholar Rock by 9.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 502,793 shares of the company's stock worth $4,027,000 after purchasing an additional 42,139 shares during the last quarter. Barclays PLC lifted its position in Scholar Rock by 103.4% during the 3rd quarter. Barclays PLC now owns 165,449 shares of the company's stock valued at $1,324,000 after purchasing an additional 84,118 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Scholar Rock by 7.1% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 94,795 shares of the company's stock valued at $759,000 after purchasing an additional 6,269 shares during the period. Finally, Geode Capital Management LLC boosted its stake in shares of Scholar Rock by 8.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,543,025 shares of the company's stock valued at $12,361,000 after purchasing an additional 120,489 shares during the last quarter. 91.08% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. Wedbush reissued an "outperform" rating and set a $47.00 price target on shares of Scholar Rock in a report on Wednesday, January 29th. HC Wainwright lifted their target price on shares of Scholar Rock from $40.00 to $50.00 and gave the company a "buy" rating in a research note on Tuesday, November 26th. Finally, Truist Financial increased their price target on Scholar Rock from $36.00 to $45.00 and gave the stock a "buy" rating in a research report on Monday, November 25th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Buy" and an average target price of $40.43.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.